论文部分内容阅读
自皮质素应用于临床以来,很多学者曾先后试用强的松、氢化可的松、地塞米松制成气雾剂由气道吸入,企图减少或避免皮质素的副作用。遗憾的是上述药物因局部作用微弱,或因通过全身吸收仍出现副作用而被摒弃。1972年Brown首先用丙酸培氯松(原名二丙酸氯地米松)气雾剂(beclomethasone dipro-poionate aeroso,简称BDA)防治哮喘。取得良好疗效。BDA系人工合成的皮质素,它的效力比氢化可的松大5000倍,难溶于水,局部作用异常强大,而全身副作用微弱,被誉为治疗哮喘药物的一大进展。最近有人认为BDA较应用监测血浓度的氨茶碱疗法更有效、更安全。其应用适应证,宜较前扩大,当合理吸入β_2兴奋剂不能控制症状时,必须用BDA。中度哮喘患者尤
Since the application of cortical in clinical practice, many scholars have tried with prednisone, hydrocortisone, dexamethasone aerosol into the airway in an attempt to reduce or avoid the side effects of cortisol. It is a pity that these drugs are abandoned because of their weak local effect or their side effects caused by systemic absorption. In 1972, Brown first used the beclomethasone propionate (formerly beclomethasone dipropionate) aerosol (beclomethasone dipro-poionate aeroso, referred to as BDA) to prevent and treat asthma. Achieve good effect. BDA synthetic cortisol, its effectiveness than hydrocortisone 5000 times larger, insoluble in water, the strong local action, and systemic side effects of weak, known as the treatment of asthma drugs a major progress. Recently, some people think that BDA is more effective and safer than the application of aminophylline therapy for monitoring blood concentration. Its application indications, should be expanded compared with the previous, when the reasonable inhalation of β_2 stimulant can not control the symptoms, you must use BDA. Moderate asthma patients especially